iCo Therapeutics Inc. and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema
9/26/2011 11:22:10 AM
More...
|
iCo Therapeutics Inc. Announces Key iCo-007 Clinical Development Milestone
8/16/2011 9:41:22 AM
More...
|
iCo Therapeutics Inc. Executes Bertilimumab License with Immune Pharmaceuticals in Deal Worth $32 Million
6/24/2011 1:05:15 PM
More...
|
iCo Therapeutics Inc. Secures $10 Million Equity Line Facility
4/14/2011 11:50:02 AM
More...
|
iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing
2/22/2011 10:15:16 AM
More...
|
iCo Therapeutics Inc. Extends Investor Relations Engagement with The Trout Group
12/27/2010 9:55:55 AM
More...
|
iCo Therapeutics Inc. Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for $33 Million Plus Royalties
12/8/2010 7:31:00 AM
More...
|
iCo Therapeutics Inc. Reports Third Quarter 2010 Financial Results
11/29/2010 11:31:30 AM
More...
|
iCo Therapeutics Inc. Selected as Canada's Top 10(TM) Competition Winner
10/13/2010 11:59:32 AM
More...
|
iCo Therapeutics Inc. Oral Amphotericin Program Receives FDA Orphan Drug Status
9/29/2010 9:12:38 AM
More...
|
|